Dosing & Uses
AdultPediatric
See Pediatric Dosing & Uses
Congenital Thrombotic Thrombocytopenic Purpura
Pending FDA approval for enzyme replacement therapy of congenital thrombotic thrombocytopenic purpura (cTTP), an ADAMTS13 gene deficiency disorder
Next:
Pharmacology
Mechanism of Action
Congenital thrombotic thrombocytopenic purpura (cTTP), is an ADAM metallopeptidase with thrombospondin type 1 motif 13 (ADAMTS13) gene deficiency disorder
ADAMTS13 enzyme splices von Willebrand factor to regulate its interaction with platelets; this action is involved in platelet adhesion to form temporary clots at the site of an injury
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
